2384: Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort

Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment informed by 10 immune biomarkers that objectively measures current disease activity, while the hybrid SLEDAI (hSLEDAI) is a clinician assessed measure of disease activity. This study evaluated the association between both L-DAI and hSLEDAI and patient reported quality of life (HRQol) in a small real-world community-based, prospectively followed SLE cohort.

Methods: We conducted a retrospective analysis from a small cohort of adults with classified SLE longitudinally and serially followed at the Mayo clinic from 2018 to 2021. L-DAI, hSLEDAI were collected quarterly for 12 months but clinicians were blinded to the L-DAI score throughout the study period. HRQol was assessed using the LupusPRO score (0-100 scale) at each visit. Linear regression was used to evaluate the association between HRQol and both L-DAI and hSLEDAI scores.

Results: Among 30 patients contributing to 145 visits, 27 (90%) were female and 3 (10.00%) were male. HRQol ranged from 28 to 100 (mean= 70.79 ± 16.34). In multivariable linear regression, both an increase in hSLEDAI (β = -0.89, p= 0.006) and an increase in L-DAI (β = -0.25, p= 0.020) were independently associated with a lower HRQol.

Conclusion: Our study demonstrated that both L-DAI and hSLEDAI were significantly associated with patient reported HRQol. In fact, an incremental increase in both L-DAI and hSLEDAI correlated with a decrease in patient reported quality of life. These findings highlight the utility of L-DAI and hSLEDAI in assessing disease activity and patient-reported quality of life measures. However, larger, more diverse patient cohorts are needed to validate these findings.